Serum TGF-β1 and SMAD3 levels are closely associated with coronary artery disease
Open Access
- 17 February 2014
- journal article
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 14 (1) , 18
Abstract
Coronary artery disease (CAD) is one of the most common diseases leading to mortality and morbidity worldwide. There is considerable debate on whether serum transforming growth factor β1 (TGF-β1) levels are associated with long-term major adverse cardiovascular events in patients with CAD, and to date, no study has specifically addressed levels in patients with different degrees of CAD severity.Keywords
This publication has 27 references indexed in Scilit:
- Genetics of Human Cardiovascular DiseaseCell, 2012
- Genetic Basis of Atherosclerosis: Insights From Mice and HumansCirculation Research, 2012
- Transforming growth factor (TGF)-β signaling in cardiac remodelingJournal of Molecular and Cellular Cardiology, 2011
- Reactive oxygen species in cardiovascular diseaseFree Radical Biology and Medicine, 2011
- Characterization of primary and restenotic atherosclerotic plaque from the superficial femoral artery: Potential role of Smad3 in regulation of SMC proliferationJournal of Vascular Surgery, 2009
- 'Correction:' Serum transforming growth factor beta-1 (TGF-beta-1) levels in diabetic patients are not associated with pre-existent coronary artery diseaseCardiovascular Diabetology, 2007
- The role of TGF-β signaling in myocardial infarction and cardiac remodelingCardiovascular Research, 2007
- Smad-dependent and Smad-independent pathways in TGF-β family signallingNature, 2003
- Prognostic significance of plasma concentrations of transforming growth factor-β in patients with coronary artery diseaseCoronary Artery Disease, 2002
- Altered plasma levels of cytokines in patients with ischemic heart diseaseCoronary Artery Disease, 1997